Arrowhead Research Corporation
 
insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr
PRESS RELEASE
April 20, 2010
Investor Relations Contacts:

Brandi Floberg
The Piacente Group, Inc.
212-481-2050
ir@arrowres.com

 


ARROWHEAD TO PRESENT AT UPCOMING INVESTOR CONFERENCES


PASADENA, Calif. – April 20, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) announced today that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the following investor conferences:

  • MDB Bright Lights Conference on May 11, 2010 at 1:30 pm PT in San Francisco, CA. Bright Lights will feature more than 40 of the "Best and Brightest" IP leaders identified by MDB's PatentVest IP intelligence platform as possessing technology leadership and potentially disruptive innovation.
  • Rodman & Renshaw's 6th Annual Global Healthcare Conference on May 17, 2010 at 11:55 am BST (6:55 am ET) in London, UK. An audio and slide webcast of the presentation will be available under the "Presentations and Events" page on the "Investor" section of Arrowhead's website at http://www.arrowres.com/conference.html. Following the live presentation, archives will be available for 90 days.

To request a one-on-one meeting with Dr. Anzalone at either conference, please contact Brandi Floberg at ir@arrowres.com or call 212-481-2050.

 




About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.